12:00 AM
 | 
Jun 05, 2000
 |  BC Week In Review  |  Company News  |  Deals

Medigen Biotechnology Corp., Progen Industries deal

The companies will develop PGL's PI-88 sulfated mannopentaose phosphate to treat cancer and cardiovascular disease. Medigen will fund one Phase II trial in either advanced liver cancer, nose and throat cancer or mouth cancer; one...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >